Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 24 Mar 2022
Leaked TRIPS proposal misguided about improving global COVID-19 vaccination rates
24 March 2022 - The leaked proposal on the waiver on intellectual property rights for COVID-19 vaccines is misguided and ...
Posted by Michael Wonder on 24 Mar 2022
Pressured by patients, FDA reviews ALS drug with modest data
25 March 2022 - The FDA meets next week to review a closely watched drug for ALS, or Lou Gehrig’s ...
Posted by Michael Wonder on 24 Mar 2022
Priorities for NICE in health and social care
23 March 2022 - Over the past two years there has been an unprecedented increase in medical research, the NHS has ...
Posted by Michael Wonder on 24 Mar 2022
Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
24 March 2022 - Even as prices rose substantially in the U.S. over a recent 12 year period, a new ...
Posted by Michael Wonder on 24 Mar 2022
Abbott's FreeStyle Libre is first and only CGM system to gain expanded reimbursement in Japan to include all people with diabetes who use insulin
24 March 2022 - Without expanded coverage, continuous glucose monitoring reimbursements are limited to segment of people with diabetes who require ...
Posted by Michael Wonder on 24 Mar 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis of COVID-19
24 March 2022 - Recommendation based on Phase 3 PROVENT trial showing a significant reduction in the risk of developing ...
Posted by Michael Wonder on 24 Mar 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell ...
Posted by Michael Wonder on 24 Mar 2022
Fresenius Kabi announces FDA approval of SMOFlipid lipid injectable emulsion for paediatric patients requiring parenteral nutrition
24 March 2022 - First and only four-oil lipid injectable emulsion indicated for paediatric parenteral nutrition, including term and preterm neonates. ...
Posted by Michael Wonder on 24 Mar 2022
U.S. FDA approves streamlined process for initiating HIV therapy with Cabenuva (cabotegravir and rilpivirine), the first and only complete long-acting injectable HIV treatment
24 March 2022 - Adults living with HIV now have an option to start injectable regimen without the need for ...
Posted by Michael Wonder on 24 Mar 2022
Pfizer granted FDA breakthrough therapy designation for respiratory syncytial virus vaccine candidate for the prevention of RSV in older adults
24 March 2022 - Pfizer today announced that its respiratory syncytial virus vaccine candidate, PF-06928316 or RSVpreF, received breakthrough therapy ...
Posted by Michael Wonder on 24 Mar 2022
Fennec Pharmaceuticals resubmits new drug application to the U.S. FDA for Pedmark
24 March 2022 - Fennec Pharmaceuticals today announced the resubmission of its new drug application to the U.S. FDA for ...
Posted by Michael Wonder on 24 Mar 2022
Lilly announces complete response letter for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with non-squamous non-small cell lung cancer
24 March 2022 - Eli Lilly today announced that the U.S. FDA has issued a complete response letter (CRL) for ...
Posted by Michael Wonder on 24 Mar 2022
Moderna finalises strategic partnership with Australian Government
23 March 2022 - On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory ...
Posted by Michael Wonder on 24 Mar 2022
TGA approves new medicine for patients with multiple sclerosis
24 March 2022 - Ponesimod is a sphingosine 1 phosphate receptor 1 modulator. ...
Posted by Michael Wonder on 24 Mar 2022
COVID-19 vaccine weekly safety report (24 March 2022)
24 March 2022 - To 20 March 2022, the TGA has received 485 reports which have been assessed as likely to ...